News: EPA wraps up two-year permit system review

1996 ◽  
Vol 30 (7) ◽  
pp. 287A-287A
Author(s):  
Jeff Johnson
Keyword(s):  
2015 ◽  
Vol 25 (4) ◽  
pp. 56
Author(s):  
Maomao HUANG ◽  
Weiqiang MU ◽  
Guohua ZHENG

2013 ◽  
Author(s):  
Russ S. Kotwal ◽  
Frank K. Butler ◽  
Erin P. Edgar ◽  
Stacy A. Shackelford ◽  
Donald R. Bennett ◽  
...  

2021 ◽  
Vol 35 (11) ◽  
Author(s):  
Valentina L. Stolyarova ◽  
Viktor A. Vorozhtcov ◽  
Sergey I. Lopatin ◽  
Sergey M. Shugurov ◽  
Elizaveta P. Simonenko ◽  
...  

Cytokine ◽  
2021 ◽  
Vol 141 ◽  
pp. 155441
Author(s):  
Xin Zhou ◽  
Bo Tian ◽  
Hai-Bin Han

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hao Chen ◽  
Hiromi Matsumoto ◽  
Nobuyuki Horita ◽  
Yu Hara ◽  
Nobuaki Kobayashi ◽  
...  

AbstractRisk factors associated with mortality in invasive pneumococcal disease remain unclear. The present work is a meta-analysis of studies that enrolled only patients with invasive pneumococcal disease and reported on mortality. Potentially eligible reports were identified from PubMed, CHAHL, and Web of Science, comprising 26 reports in total. Overall mortality for invasive pneumococcal disease was reported as 20.8% (95% confidence interval (CI) 17.5–24%). Factors associated with mortality were age (odds ratio (OR) 3.04, 95% CI 2.5–3.68), nursing home (OR 1.62, 95% CI 1.13–2.32), nosocomial infection (OR 2.10, 95% CI 1.52–2.89), septic shock (OR 13.35, 95% CI 4.54–39.31), underlying chronic diseases (OR 2.34, 95% CI 1.78–3.09), solid organ tumor (OR 5.34, 95% CI 2.07–13.74), immunosuppressed status (OR 1.67, 95% CI 1.31–2.14), and alcohol abuse (OR 3.14, 95% CI 2.13–4.64). Mortality rates with invasive pneumococcal disease remained high, and these findings may help clinicians provide appropriate initial treatment for this disease.


Sign in / Sign up

Export Citation Format

Share Document